These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 29208432)

  • 1. Go, no-go decision making for phase 3 clinical trials: ACT IV revisited.
    Nguyen HTN; Grogan P; Robins HI
    Lancet Oncol; 2017 Dec; 18(12):e708. PubMed ID: 29208432
    [No Abstract]   [Full Text] [Related]  

  • 2. Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.
    Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH
    Lancet Oncol; 2017 Dec; 18(12):e709-e710. PubMed ID: 29208433
    [No Abstract]   [Full Text] [Related]  

  • 3. Single-arm phase IIA clinical trials with go/no-go decisions.
    Zhong B
    Contemp Clin Trials; 2012 Nov; 33(6):1272-9. PubMed ID: 22796490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian paradigm for decision-making in proof-of-concept trials.
    Pulkstenis E; Patra K; Zhang J
    J Biopharm Stat; 2017; 27(3):442-456. PubMed ID: 28166459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision-making in early clinical drug development.
    Frewer P; Mitchell P; Watkins C; Matcham J
    Pharm Stat; 2016 May; 15(3):255-63. PubMed ID: 26991401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of phase 2 interim analysis to expedite drug development decisions.
    Huang J; Das A; Burger HU; Zhong W; Zhang W; Lieberman G
    Contemp Clin Trials; 2014 Jul; 38(2):235-44. PubMed ID: 24854415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A varying-stage adaptive phase II/III clinical trial design.
    Dong G
    Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "It is not the fading candle that one expects": general practitioners' perspectives on life-preserving versus "letting go" decision-making in end-of-life home care.
    Sercu M; Renterghem VV; Pype P; Aelbrecht K; Derese A; Deveugele M
    Scand J Prim Health Care; 2015; 33(4):233-42. PubMed ID: 26654583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Joint probability of statistical success of multiple phase III trials.
    Zhang J; Zhang JJ
    Pharm Stat; 2013; 12(6):358-65. PubMed ID: 24106067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive power to assist phase 3 go/no go decision based on phase 2 data on a different endpoint.
    Hong S; Shi L
    Stat Med; 2012 Apr; 31(9):831-43. PubMed ID: 22302442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in clinical trials mandated by the advent of meta-analysis.
    Chalmers TC; Lau J
    Stat Med; 1996 Jun; 15(12):1263-8; discussion 1269-72. PubMed ID: 8817800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
    Carroll KJ
    J Biopharm Stat; 2013; 23(5):1188-200. PubMed ID: 23957523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision.
    Roberts TG; Lynch TJ; Chabner BA
    J Clin Oncol; 2003 Oct; 21(19):3683-95. PubMed ID: 14512401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasound revisited.
    Midwifery Today Int Midwife; 2002; (64):28; author reply 28-9. PubMed ID: 12526591
    [No Abstract]   [Full Text] [Related]  

  • 15. [Decision making in clinical research: a statistical approach].
    Lacaine F; Huguier M
    Gastroenterol Clin Biol; 1980 Nov; 4(11):754-7. PubMed ID: 7461386
    [No Abstract]   [Full Text] [Related]  

  • 16. Designing prospective clinical pharmacogenomic (PG) trials: meeting report on drug development strategies to enhance therapeutic decision making.
    Trepicchio WL; Essayan D; Hall ST; Schechter G; Tezak Z; Wang SJ; Weinreich D; Simon R
    Pharmacogenomics J; 2006; 6(2):89-94. PubMed ID: 16402088
    [No Abstract]   [Full Text] [Related]  

  • 17. Exploring stop-go decision zones at rural high-speed intersections with flashing green signal and insufficient yellow time in China.
    Tang K; Xu Y; Wang F; Oguchi T
    Accid Anal Prev; 2016 Oct; 95(Pt B):470-478. PubMed ID: 26896300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analytical approach to assess the predictive value of biomarkers in Phase II decision making.
    Nikolakopoulos S; van der Wal WM; Roes KC
    J Biopharm Stat; 2013; 23(5):1106-23. PubMed ID: 23957519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions.
    Chen C; Beckman RA
    J Biopharm Stat; 2009; 19(3):424-36. PubMed ID: 19384686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of the decision-making process for the selection of therapeutics to undergo clinical testing for spinal cord injury in the North American Clinical Trials Network.
    Guest J; Harrop JS; Aarabi B; Grossman RG; Fawcett JW; Fehlings MG; Tator CH
    J Neurosurg Spine; 2012 Sep; 17(1 Suppl):94-101. PubMed ID: 22985376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.